Literature DB >> 20167254

Erythropoietin promotes spinal cord-derived neural progenitor cell proliferation by regulating cell cycle.

Y Wang1, M Yao, C Zhou, D Dong, Y Jiang, G Wei, X Cui.   

Abstract

Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells by binding to its specific transmembrane receptor (EPOR). The presence of EPO and its receptor in the CNS suggests a different function for EPO other than erythropoiesis. The purpose of the present study was to examine EPOR expression and the role of EPO in the proliferation of neonatal spinal cord-derived neural progenitor cells. The effect of EPO on cell cycle progression was also examined, as well as the signaling cascades involved in this process. Our results showed that EPOR was present in the neural progenitor cells and EPO significantly enhanced their proliferation. Cell cycle analysis of EPO-treated neural progenitor cells indicated a reduced percentage of cells in G0/G1 phase, whereas the cell proliferation index (S phase plus G2/M phase) was increased. EPO also increased the proportion of 5-bromo-2-deoxyuridine (BrdU)-positive cells. With respect to the cell cycle signaling, we examined the cyclin-dependent kinases D1, D2 and E, and cyclin-dependent kinase inhibitors, p21cip1, p27kip1 and p57kip2. No significant differences were observed in the expression of these transcripts after EPO administration. Interestingly, the anti-apoptotic factors, mcl-1 and bcl-2 were significantly increased twofold. Moreover, these specific effects of EPO were eliminated by incubation of the progenitor cells with anti-EPO neutralizing antibody. Those observations suggested that EPO may play a role in normal spinal cord development by regulating cell proliferation and apoptosis. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167254     DOI: 10.1016/j.neuroscience.2010.02.007

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Authors:  Jessica Amlin-Van Schaick; Sungjin Kim; Karl W Broman; Karlyne M Reilly
Journal:  Mamm Genome       Date:  2011-12-08       Impact factor: 2.957

2.  EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.

Authors:  Yu Jia; Shi-Jing Mo; Qi-Qi Feng; Ma-Li Zhan; Li-Si OuYang; Jia-Chang Chen; Yu-Xin Ma; Jia-Jia Wu; Wan-Long Lei
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

3.  Effects of erythropoietin in murine-induced pluripotent cell-derived panneural progenitor cells.

Authors:  Nils Offen; Johannes Flemming; Hares Kamawal; Ruhel Ahmad; Wanja Wolber; Christian Geis; Holm Zaehres; Hans R Schöler; Hannelore Ehrenreich; Albrecht M Müller; Anna-Leena Sirén
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

4.  Protective effect of adenovirus-mediated erythropoietin expression on the spiral ganglion neurons in the rat inner ear.

Authors:  Cheng Zhong; Zhendong Jiang; Qiang Guo; Xueyuan Zhang
Journal:  Int J Mol Med       Date:  2018-02-05       Impact factor: 4.101

Review 5.  Regulation of Inflammatory Cytokines for Spinal Cord Injury Repair Through Local Delivery of Therapeutic Agents.

Authors:  Hao Ren; Xuri Chen; Mengya Tian; Jing Zhou; Hongwei Ouyang; Zhiyong Zhang
Journal:  Adv Sci (Weinh)       Date:  2018-07-31       Impact factor: 16.806

6.  Erythropoietin in brain development and beyond.

Authors:  Mawadda Alnaeeli; Li Wang; Barbora Piknova; Heather Rogers; Xiaoxia Li; Constance Tom Noguchi
Journal:  Anat Res Int       Date:  2012-02-26

7.  Neuroprotective effect of astrocyte-derived IL-33 in neonatal hypoxic-ischemic brain injury.

Authors:  Mengya Jiao; Xiangyong Li; Liying Chen; Xiaodi Wang; Baohong Yuan; Tao Liu; Qun Dong; Hanfang Mei; Hui Yin
Journal:  J Neuroinflammation       Date:  2020-08-28       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.